EG24464A - Epothilone derivatives - Google Patents

Epothilone derivatives

Info

Publication number
EG24464A
EG24464A EG79298A EG79298A EG24464A EG 24464 A EG24464 A EG 24464A EG 79298 A EG79298 A EG 79298A EG 79298 A EG79298 A EG 79298A EG 24464 A EG24464 A EG 24464A
Authority
EG
Egypt
Prior art keywords
epothilone derivatives
epothilone
derivatives
Prior art date
Application number
EG79298A
Other languages
English (en)
Inventor
Gregory D Vite
Robert M Borzilleri
Soong-Hoon Kim
James A Johnson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26729990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG24464A publication Critical patent/EG24464A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EG79298A 1997-07-08 1998-07-07 Epothilone derivatives EG24464A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5195197P 1997-07-08 1997-07-08
US6752497P 1997-12-04 1997-12-04

Publications (1)

Publication Number Publication Date
EG24464A true EG24464A (en) 2009-07-16

Family

ID=26729990

Family Applications (1)

Application Number Title Priority Date Filing Date
EG79298A EG24464A (en) 1997-07-08 1998-07-07 Epothilone derivatives

Country Status (32)

Country Link
US (10) US6605599B1 (fr)
EP (4) EP1526133A1 (fr)
JP (2) JP4090514B2 (fr)
KR (1) KR100569041B1 (fr)
CN (1) CN100384834C (fr)
AR (1) AR013358A1 (fr)
AT (2) ATE426598T1 (fr)
AU (1) AU731497B2 (fr)
BG (1) BG64952B1 (fr)
BR (1) BRPI9810555A8 (fr)
CA (1) CA2296012C (fr)
CO (1) CO4940501A1 (fr)
CZ (1) CZ297904B6 (fr)
DE (2) DE69832294T2 (fr)
DK (1) DK1019389T3 (fr)
EE (1) EE04566B1 (fr)
EG (1) EG24464A (fr)
ES (2) ES2251088T3 (fr)
GE (1) GEP20032897B (fr)
HU (1) HU227444B1 (fr)
ID (1) ID23771A (fr)
IL (1) IL133613A (fr)
LV (1) LV12569B (fr)
MY (1) MY124151A (fr)
NO (1) NO322494B1 (fr)
NZ (1) NZ501198A (fr)
PE (1) PE104599A1 (fr)
PL (1) PL197404B1 (fr)
RO (1) RO120340B1 (fr)
TR (1) TR200000065T2 (fr)
TW (1) TW562802B (fr)
WO (1) WO1999002514A2 (fr)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
CA2299608A1 (fr) 1997-08-09 1999-02-18 Schering Aktiengesellschaft Nouveaux derives d'epothilone, leur procede de fabrication et leur utilisation pharmaceutique
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
AU2795000A (en) 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
CZ20012886A3 (cs) * 1999-02-11 2001-11-14 Schering Aktiengesellschaft Deriváty epothilonu, způsob jejich přípravy a jejich farmaceutické pouľití
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
AU772750C (en) * 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
CA2385528C (fr) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2001092255A2 (fr) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Derives d'epothilone, procedes de production et methodes d'utilisation
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002213248A1 (en) 2000-10-13 2002-04-22 The University Of Mississipi Synthesis of epothilones and relates analogs
PL207720B1 (pl) * 2001-01-25 2011-01-31 Bristol Myers Squibb Co Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
EP1353667A1 (fr) * 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
CZ20032021A3 (cs) 2001-01-25 2004-05-12 Bristol@Myersásquibbácompany Způsoby podávání analogů epothilonu při léčbě rakoviny
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2002066038A1 (fr) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Traitement de tumeurs refractaires a l'aide de derives d'epothilone
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
KR20030084952A (ko) 2001-02-27 2003-11-01 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 에포틸론의 분해 및 에티닐 치환된 에포틸론
CA2440555A1 (fr) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilones et d'agents chimiotherapeutiques servant au traitement de maladies proliferatives
WO2002098868A1 (fr) 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Derives d'epothilone
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
RU2346686C2 (ru) 2002-01-14 2009-02-20 Новартис Аг Комбинации, включающие эпотилоны и антиметаболиты
EP1340498A1 (fr) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Utilisation d'épothilones dans le traitement de maladies du cerveau associées aux processus de prolifération
WO2003077903A1 (fr) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Derives c12-cyano epothilone
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE10232094A1 (de) * 2002-07-15 2004-02-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 5-Thiaepothilone und 15-disubstituierte Epothilone
WO2004018478A2 (fr) * 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, leurs intermediaires, leurs analogues et leurs utilisations
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR20050053681A (ko) 2002-09-23 2005-06-08 브리스톨-마이어스 스큅 컴퍼니 에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의ｘ-선 결정 구조
BR0314555A (pt) * 2002-10-11 2005-08-09 Dana Farber Cancer Inst Inc Derivados de epotilona para o tratamento de mieloma múltiplo
EP1567487A4 (fr) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
ES2330517T3 (es) * 2002-11-28 2009-12-11 Wolfgang Richter Derivados de tia-epotilona para el tratamiento del cancer.
WO2004052361A1 (fr) * 2002-12-09 2004-06-24 Novartis Ag Stabilisateurs de microtubules utilises dans le traitement de la stenose dans des stents
GB0230024D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
CN101177425B (zh) * 2003-01-28 2012-07-18 北京华昊中天生物技术有限公司 一类新型埃坡霉素化合物及其制备方法和用途
WO2004071440A2 (fr) 2003-02-06 2004-08-26 Bristol-Myers Squibb Company Composes a base de thiazolyle utilises comme inhibiteurs de kinases
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2008200555C1 (en) * 2003-03-14 2011-12-15 Novartis Ag Treatment of proliferative diseases with epothilone derivatives and radiation
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DE10344882A1 (de) * 2003-09-26 2005-04-21 Morphochem Ag Komb Chemie Neue Makrocyclen zur Behandlung von Krebserkrankungen
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
WO2005054429A2 (fr) * 2003-11-19 2005-06-16 The University Of Mississippi Synthese du synthon ceto-acide en c1-c6 des epothilones
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (fr) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'epothilone pour le traitement de defauts de connectivité neuronale comme par exemple la schizophrenie et l'autisme
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006017761A2 (fr) * 2004-08-05 2006-02-16 Emory University Analogues d'epothilone en tant qu'agents therapeutiques
EP1640004A1 (fr) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Utilisation des epothilones pour le traitement des metastases osseuses ou du cancer des os
MX2007005763A (es) 2004-11-18 2007-07-20 Squibb Bristol Myers Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
EP1824458A1 (fr) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Bille enrobee de keratine comprenant de l'epothilone ou un analogue d'epothilone, ainsi que preparation et administration de cette bille
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (fr) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Formulations parenterales stables et tolérables des substances de haut réactivité ayant une solubilité basse ou inexistante dans l'eau
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP2009532035A (ja) 2006-03-31 2009-09-10 ブリストル−マイヤーズ スクイブ カンパニー 微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
KR20090095626A (ko) 2006-12-04 2009-09-09 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 ＣｐＧ 리치 ＤＮＡ를 이용한 조성물 및 암 치료 방법
AU2008212788A1 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
JP2010528115A (ja) 2007-05-25 2010-08-19 ブリストル−マイヤーズ スクイブ カンパニー エポチロン化合物およびアナログの製造方法
US20090076099A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched ixabepilone
EP2065054A1 (fr) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinaisons comprenant une prostaglandine et leurs utilisations
EP2070521A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanoparticules à surface modifiée
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
KR20100100949A (ko) 2008-01-08 2010-09-15 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
NZ588555A (en) * 2008-04-24 2012-06-29 Bristol Myers Squibb Co Use of epothilone d in treating tau-associated diseases including alzheimer's disease
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (fr) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Composition polymère stable comprenant un copolymère séquencé d'épothilone et amphiphile
JP4500951B1 (ja) * 2009-08-07 2010-07-14 学校法人神戸学院 Ｄｎａ合成酵素阻害剤
WO2011049625A1 (fr) 2009-10-20 2011-04-28 Mansour Samadpour Procédé de criblage d'aflatoxine dans des produits
SG10201500895XA (en) 2009-11-05 2015-04-29 Rhizen Pharmaceuticals Sa Chromen-4-one Derivatives As Kinase Modulators
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
EP3450432A1 (fr) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Nouveaux composés 3,5 disubstitués-3h-imidazo[4,5-b] pyridine et 3,5-disubstitués-3h-[1,2,3]triazolo[4,5-b] pyridine utilisés comme modulateurs de kinases de protéine
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
KR20130086534A (ko) 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
CN101906099A (zh) * 2010-07-16 2010-12-08 泰州市今朝伟业精细化工有限公司 一种埃博霉素d-内酰胺衍生物化学合成方法
BR112013018534B1 (pt) 2011-01-20 2021-04-06 Board Of Regents, The University Of Texas System Agente de contraste, seus métodos de preparação, e produto de combinação
US20140087309A1 (en) * 2011-04-01 2014-03-27 The Research Foundation Of State University Of New York Olefin-triggered acid amplifiers
JP2014511849A (ja) * 2011-04-01 2014-05-19 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 安定化された酸増幅剤
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
CA2838387A1 (fr) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Utilisation de composes metallocenes pour le traitement du cancer
CA2837840C (fr) 2011-06-10 2020-08-04 Mersana Therapeutics, Inc. Conjugues de medicament-proteine-polymere
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
WO2013008091A1 (fr) * 2011-07-13 2013-01-17 Xellia Pharmaceuticals Aps Fabrication de dérivés d'épothiline et leur utilisation
ES2458220T3 (es) 2011-09-12 2014-04-30 Agfa-Gevaert Métodos para el marcado por láser color de precursores de documento de seguridad
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
AU2012356894B2 (en) 2011-12-23 2018-01-18 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
WO2014009426A2 (fr) 2012-07-13 2014-01-16 Innate Pharma Criblage d'anticorps conjugués
EP2916872B1 (fr) 2012-11-09 2019-02-27 Innate Pharma Etiquettes de reconnaissance pour la conjugaison à médiation par la tgase
WO2014075391A1 (fr) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 Composé du platine et de dérivé de l'acide malonique ayant un groupe partant contenant un groupe amino ou alkylamino
WO2014089177A2 (fr) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
CA2892863C (fr) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Echafaudage polymere fonde sur des filaments helicoidaux apparies (phf) pour l'administration ciblee de medicaments
EP2931316B1 (fr) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Conjugués hydroxy-polymère-médicament-protéine
US9309259B2 (en) * 2013-03-08 2016-04-12 Scinopharm Taiwan, Ltd. Process for ixabepilone, and intermediates thereof
WO2014140300A1 (fr) 2013-03-15 2014-09-18 Innate Pharma Conjugaison d'anticorps en phase solide médiée par la tgase
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EP3007692A1 (fr) 2013-06-11 2016-04-20 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
WO2014202773A1 (fr) 2013-06-20 2014-12-24 Innate Pharma Conjugaison enzymatique de polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
KR102572149B1 (ko) 2013-10-11 2023-08-30 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
US10341459B2 (en) 2015-09-18 2019-07-02 International Business Machines Corporation Personalized content and services based on profile information
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018004338A1 (fr) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Tétrazine clivable utilisée dans l'activation de médicaments bio-orthogonaux
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019092148A1 (fr) 2017-11-10 2019-05-16 Innate Pharma Anticorps avec des résidus de glutamine fonctionnalisés
CA3099421C (fr) 2018-05-04 2025-05-06 Tagworks Pharmaceuticals B.V. Composés comprenant un liant pour accroître la stabilité de transcyclooctène
WO2019212356A1 (fr) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tétrazines pour un rendement élevé de conjugaison de chimie click in vivo et un rendement élevé de libération de chimie click
MX2021004906A (es) 2018-10-29 2021-09-10 Mersana Therapeutics Inc Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
CN115135628A (zh) 2019-06-17 2022-09-30 泰克沃尔科斯制药有限公司 快速高效点击释放的化合物
BR112022013685A2 (pt) 2020-01-10 2022-09-06 R Pharm Us Operating Llc Composições de ixabepilona
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4399283A2 (fr) 2021-09-06 2024-07-17 Veraxa Biotech GmbH Nouveaux variants d'aminoacyl-arnt synthétase pour l'expansion de code génétique dans des eucaryotes
EP4437005A1 (fr) 2021-11-25 2024-10-02 Veraxa Biotech GmbH Conjugués anticorps-charge utile améliorés (apc) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
EP4186529B1 (fr) 2021-11-25 2025-07-09 Veraxa Biotech GmbH Conjugués anticorps-charge utile améliorés (apcs) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
WO2023104941A1 (fr) 2021-12-08 2023-06-15 European Molecular Biology Laboratory Charges utiles hydrophiles fonctionnalisées à la tétrazine destinées à la préparation de conjugués de ciblage
US20250114489A1 (en) 2022-02-15 2025-04-10 Tagworks Pharmaceuticals B.V. Masked il12 protein
CN119836306A (zh) 2022-07-15 2025-04-15 费恩治疗有限公司 与cdcp1结合的抗体药物缀合物和其用途
AU2023358214A1 (en) 2022-10-12 2025-05-08 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
CN120569216A (zh) 2023-01-20 2025-08-29 巴斯夫欧洲公司 稳定型生物聚合物组合物、其制造和用途
AU2024237490A1 (en) 2023-03-10 2025-09-25 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker
AU2024300552A1 (en) 2023-07-27 2026-01-29 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025056807A1 (fr) 2023-09-15 2025-03-20 Basf Se Compositions biopolymère stabilisées, leur fabrication et utilisation
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations
WO2025174248A1 (fr) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctènes à libération avec "fonction ou"
WO2026043376A1 (fr) 2024-08-22 2026-02-26 Tagworks Pharmaceuticals B.V. Formulations de trans-cyclooctène
WO2026064527A1 (fr) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction covalente ciblant kras comprenant une charge utile d'inhibiteur de tubuline
WO2026064520A1 (fr) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction covalente ciblant kras et comprenant une charge utile inhibitrice de tubuline
WO2026078060A1 (fr) 2024-10-08 2026-04-16 Basf Se Alcoxylates de tocophérol pour la stabilisation de biopolymères
WO2026090323A1 (fr) 2024-10-23 2026-04-30 Incyte Corporation Polythérapie utilisant un inhibiteur de kras g12d, un analogue nucléosidique et/ou un inhibiteur des microtubules et son utilisation dans le traitement du cancer

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272525A (en) 1978-10-23 1981-06-09 Schering Corporation Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them
IL69666A (en) 1982-09-13 1987-10-20 Lilly Co Eli 20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use
US4820695A (en) 1982-09-13 1989-04-11 Eli Lilly And Company C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
JPH03101679A (ja) 1989-09-14 1991-04-26 Sankyo Co Ltd リゾキシン誘導体
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5789397A (en) 1991-01-08 1998-08-04 Bone Care International, Inc. Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
CA2067520A1 (fr) 1991-05-02 1992-11-03 Tats Matsuoka Traitement de la mastite
US5217960A (en) 1991-05-03 1993-06-08 Abbott Laboratories Erythromycin derivatives
JP3101679B2 (ja) 1991-07-02 2000-10-23 株式会社ニチレイ 動物細胞の凍結保存用血清不含培地及び保存方法
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
TW226373B (fr) 1992-07-15 1994-07-11 Pfizer
EP0586738A1 (fr) 1992-09-11 1994-03-16 Boehringer Ingelheim Vetmedica Gmbh Composition thérapeutique à activité antimicrobienne accrue chez le poisson contenant un dérivé d'une benzylamine et une substance antimicrobienne
NZ250465A (en) 1992-12-21 1995-10-26 Lilly Co Eli Bactericidal composition; contains macrolide antibiotic, use for treating aquatic species
US5677287A (en) 1993-03-18 1997-10-14 Pfizer Inc. Antibacterial 16-membered ring macrolides containing olefins at C-20
DE4316836A1 (de) 1993-05-19 1994-11-24 Knoell Hans Forschung Ev Tetrahydrofuranyl-propionsäure, ein Verfahren zu ihrer Herstellung und Verwendung derselben
EP0708770B1 (fr) 1993-07-15 1997-04-16 Pfizer Inc. Derives d'amides de macrolides antibiotiques a noyau de 16 elements
EP0639644A1 (fr) 1993-08-16 1995-02-22 Ciba-Geigy Ag Nouveaux macrolides et leur utilisation
US5763429A (en) 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
AU3121095A (en) 1994-09-22 1996-04-09 Pfizer Inc. Antibiotic macrolides
AU3953595A (en) 1994-10-07 1996-05-02 Merck & Co., Inc. Process for assessing tubulin protein polymerization
IL117200A0 (en) 1995-02-21 1996-06-18 Schering Ag Diethylenetriamine-pentaacetic acid monoamide derivatives pharmaceutical compostions containing the same and processes for the preparation thereof
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
US5515936A (en) * 1995-07-10 1996-05-14 Vehicules Ts Bellechasse Ltee Track tensioning system for endless track propelled vehicle
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
WO1997019088A1 (fr) 1995-11-21 1997-05-29 Hoechst Celanese Corporation Nouvelles molecules optiques non lineaires et polymeres les contenant
EP0778283A3 (fr) 1995-12-05 1998-01-28 Pfizer Inc. Macrolides antibiotiques
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
GB9623944D0 (en) 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
AT404477B (de) 1997-01-15 1998-11-25 Thal Hermann Dipl Ing Gebündeltes spannglied und verfahren zur herstellung desselben
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
EP1201666A3 (fr) 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilones à chaine latérale modifiée
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (fr) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Metathese olefinique selective de substrats bifonctionnels ou polyfonctionnels dans du dioxyde de carbone comprime en tant que milieu de reaction
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2184307T3 (es) 1997-07-16 2003-04-01 Schering Ag Derivados de tiazol, procedimiento para su preparacion y su utilizacion.
CA2299608A1 (fr) 1997-08-09 1999-02-18 Schering Aktiengesellschaft Nouveaux derives d'epothilone, leur procede de fabrication et leur utilisation pharmaceutique
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
MY125921A (en) 1998-02-05 2006-08-30 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6136630A (en) * 1998-06-04 2000-10-24 The Regents Of The University Of Michigan Method of making a micromechanical device from a single crystal semiconductor substrate and monolithic sensor formed thereby
WO2000000485A1 (fr) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Derives d'epothilone, leur procede de production, produits intermediaires et leur utilisation pharmaceutique
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
AU2795000A (en) * 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
NZ513268A (en) 1999-02-18 2004-05-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
AU772750C (en) 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1353667A1 (fr) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
CZ20032021A3 (cs) 2001-01-25 2004-05-12 Bristol@Myersásquibbácompany Způsoby podávání analogů epothilonu při léčbě rakoviny
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
WO2002066038A1 (fr) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Traitement de tumeurs refractaires a l'aide de derives d'epothilone
CA2440555A1 (fr) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilones et d'agents chimiotherapeutiques servant au traitement de maladies proliferatives
US7026362B2 (en) 2001-10-09 2006-04-11 Simax Technologies, Inc. Sol-gel process utilizing reduced mixing temperatures

Also Published As

Publication number Publication date
DE69840693D1 (de) 2009-05-07
US8921542B2 (en) 2014-12-30
DE69832294T2 (de) 2006-05-24
AU731497B2 (en) 2001-03-29
US20150080440A1 (en) 2015-03-19
USRE41893E1 (en) 2010-10-26
IL133613A0 (en) 2001-04-30
ATE426598T1 (de) 2009-04-15
JP2002512634A (ja) 2002-04-23
ATE309236T1 (de) 2005-11-15
AU7972098A (en) 1999-02-08
USRE41911E1 (en) 2010-11-02
PL197404B1 (pl) 2008-03-31
NO20000076D0 (no) 2000-01-07
KR20010021562A (ko) 2001-03-15
ES2251088T3 (es) 2006-04-16
AR013358A1 (es) 2000-12-27
MY124151A (en) 2006-06-30
NO322494B1 (no) 2006-10-16
WO1999002514A2 (fr) 1999-01-21
CZ297904B6 (cs) 2007-04-25
EP1526133A1 (fr) 2005-04-27
BG64952B1 (bg) 2006-10-31
EP1493738A1 (fr) 2005-01-05
TR200000065T2 (tr) 2000-11-21
EP1493738B1 (fr) 2009-03-25
US8536327B2 (en) 2013-09-17
US20060287371A1 (en) 2006-12-21
US20070255055A1 (en) 2007-11-01
USRE41895E1 (en) 2010-10-26
KR100569041B1 (ko) 2006-04-10
NO20000076L (no) 2000-01-07
PE104599A1 (es) 2000-01-19
DE69832294D1 (de) 2005-12-15
EE200000013A (et) 2000-08-15
CA2296012C (fr) 2008-10-21
US6605599B1 (en) 2003-08-12
US20130331564A1 (en) 2013-12-12
HK1026905A1 (en) 2000-12-29
HUP0103111A3 (en) 2003-01-28
US20030220295A1 (en) 2003-11-27
CZ200058A3 (cs) 2001-01-17
US7125899B2 (en) 2006-10-24
JP2007291121A (ja) 2007-11-08
EP1019389A4 (fr) 2001-11-07
BR9810555A (pt) 2000-08-15
EE04566B1 (et) 2005-12-15
EP1019389B1 (fr) 2005-11-09
NZ501198A (en) 2001-09-28
HU227444B1 (en) 2011-06-28
CN100384834C (zh) 2008-04-30
EP1531153A1 (fr) 2005-05-18
BG104068A (en) 2000-09-29
HUP0103111A2 (hu) 2002-04-29
LV12569B (en) 2001-04-20
PL338003A1 (en) 2000-09-25
IL133613A (en) 2005-11-20
BRPI9810555A8 (pt) 2017-09-19
WO1999002514A3 (fr) 2001-05-10
ES2322807T3 (es) 2009-06-29
HK1031731A1 (zh) 2001-06-22
USRE43003E1 (en) 2011-12-06
CO4940501A1 (es) 2000-07-24
RO120340B1 (ro) 2005-12-30
LV12569A (en) 2000-11-20
JP4885067B2 (ja) 2012-02-29
JP4090514B2 (ja) 2008-05-28
ID23771A (id) 2000-05-11
US7241755B2 (en) 2007-07-10
CA2296012A1 (fr) 1999-01-21
CN1270589A (zh) 2000-10-18
EP1019389A2 (fr) 2000-07-19
GEP20032897B (en) 2003-02-25
TW562802B (en) 2003-11-21
DK1019389T3 (da) 2006-01-16

Similar Documents

Publication Publication Date Title
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
GB9702194D0 (en) Sulphonide derivatives
HUP0003642A3 (en) N-alkanoylphenylalanine derivatives
ZA987602B (en) N-alkanoylphenylalanine derivatives
PL334847A1 (en) Substituted 3-heterocyclyl-benzoyl derivatives
SI0928790T1 (en) Thiazole derivatives
NO20000076L (no) Epothilone-derivater
GB9809664D0 (en) a-Ketoamide derivatives
HUP9801168A3 (en) Triazinylaminostilbene derivatives
SG74686A1 (en) Thiazole derivatives
EG23802A (en) 2-Phenylpyran-4-one derivatives
GB2321457B (en) 5-Aroylnaphthalene derivatives
SI0928793T1 (en) Thiazole derivatives
IL132982A0 (en) Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives
GB9715821D0 (en) Amidino-camptothecin derivatives
ZA9810039B (en) Azoline derivatives
IL142090A0 (en) Thiazole derivatives
GB9725541D0 (en) Amino-benzothiazole derivatives
GB9701628D0 (en) Imino-aza-anthracyclinone derivatives
LT99153A (en) Epothilone derivatives
HU9803041D0 (en) Thiazole derivatives
ZA983116B (en) Arylsecocholadiene derivatives
EP1061912A4 (fr) Derives de phenanthrofuran
HU9800889D0 (en) New naphtylpiperazine derivatives
IL131159A0 (en) 4-Aminoethoxyindazole derivatives